Lecture 7: Alzheimer’s Disease 2 Flashcards

1
Q

Alzheimer’s disease

Executive Functions (EF)

A
  • Impairments of EF common in AD
    • already in early stage
    • impaired relative to HC on set shifting, flexibility (e.g. WCST), planning (e.g. ToL), inhibition (e.g. Stroop)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Executive functions

  • Stroop in AD (Bondi et al., 2002)
A

Stroop in AD (Bondi et al., 2002)

  • 51 healthy controls, 59 probable AD
  • AD - more errors word reading, color reading, color-word reading trials
  • AD - interference score impaired (CW/C)
  • No difference mild, moderate AD subgroups (Dementia Rating Scale)
    • mild AD already degree psychomotor slowing and inhibitory deficit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Executive Functions in Alzheimer Disease: A Systematic Review (Guarino et al., 2019).

A
  • Stroop – most consistently impaired
    • Accuracy
    • RTs
    • Interference

AD very mild (MMSE 26) – moderate (MMSE 16)

  • WCST – deficits inconsistent
    • problem with task difficulty
    • floor effect
  • Flanker – no consistent group differences
  • Go-NoGo – majority studies no difference

AD: MMSE 18 - 25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Language Impairments (AD) early vs later stage:

A
  • Most language related capabilities intact in early stage but impaired in later stage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Visuospatial abilities in AD:

Visual Search (Foster et al., 1999):

Mental Rotation (Lineweaver et al., 2005):

A
  • Impairments typically mild in early stage
    • severe impairments as disease progresses
    • loss of orientation – lost in familiar surroundings, even their own home
  • Visual search: feature (single feature) vs conjunction (two features) search:
    • AD slower than HC, even in feature search
    • impairment more severe in more advanced AD
  • Mental rotation
    • AD slower to respond (mentally rotate)
    • Accuracy lower in AD patients, greater decline with increasing angles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Visuospatial abilities in AD:

Clock drawing (Rouleau et al., 1992):

A

Clock drawing

  • Draw clock from memory, copy clock
  • Errors AD mainly conceptual errors, e.g.
    • drawing clock without numbers or without hands
    • setting time (10 past 11) incorrectly (Rouleau et al., 1992)
  • Clock drawing errors in AD
  • Conceptual errors - deficit accessing knowledge
  • danger with using it for screening is that often healthy elderly have difficulties with this task (but much larger in AD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Visuospatial abilities

¨Posterior cortical atrophy (PCA) – associated with AD:

A

Posterior cortical atrophy (PCA) – associated with AD

  • Predominantly AD pathology in posterior cortical regions: posterior parietal, occipital
  • visual variant AD
  • visual functions impaired, e.g. reading, object recognition (visual agnosia)
  • relatively preserved memory and language
  • Prevalence PCA unknown – 5% in sample 523 AD patients
  • Onset PCA earlier than typical amnestic AD, in 50s or 60s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Neuropsychological change

Typical pattern memory and EF impairments in early stage AD:

(Weintraub et al., 2012)

A

Typical pattern memory and EF impairments in early stage AD

  • with progression more functions affected
  • pattern impairments less distinct from other forms dementia
  • early stage dementia seems to impact memory the most compared to other functions like behavioural ones

(Picture: the larger the black bar the more severe the impairment)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Severity and profile of cognitive impairments varies with age at diagnosis. AD.

(Salmon & Bondi, 2009)

A
  • Severity and profile of cognitive impairments varies with age at diagnosis.
  • someone diagnosed below 70 mostly impaired in memory and EF, those above 80 all functions are imapaired to a similiar degree
  • patients are compared relative to healthy individuals of the same age
  • Different form AD?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Sex differences in AD:

Cognitive impairments.

A

Sex differences in AD:

  • AD more prevalent in women
  • Cognitive impairments more severe in women with AD
    • Laws et al. (2018) review 298 articles:
    • Women with AD < men with AD
      • episodic memory, semantic memory, verbal abilities, visual spatial functions
      • Effect sizes small (d= 0.2)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sex differences in AD

  • AD more prevalent in women, possible causes:
A

Genetic – APOE4 (Mielke et al., 2014)

  • Single APOE 4 allele: women 4X higher risk AD, men little increased risk
  • Autopsy study: plaques and tangles most prevalent in female APOE 4 carriers

Hormones – changes in oestrogen levels

  • Hormonal replacement therapy (HRT) in mid life can reduce risk AD ( although evidence not consistent)
    • HRT after menopause can increase risk AD

Cognitive reserve

  • Persons with more CR greater capacity to cope with brain pathology
  • Education and occupation important factors CR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Early cognitive predictors AD

A
  • Episodic memory disturbances years before diagnosis:
    • Delayed recall CVLT performance in healthy older adults predictor of subsequent progression to AD (Bondi et al, 1999)
  • Memory performance poorer in persons converting to AD 3 years later
    • learning score CVLT ( California Verbal Learning Test) distinguished normal group (controls), MCI (questionable) and converters (MCI converted to probable AD (Albert et al., 2001)
  • poorer episodic memory than persons who remained cognitively healthy 6 years before diagnosis (Bäckman et al., 2001)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Early cognitive predictors AD

  • Mild impairments episodic memory as early predictor AD
A

Mild impairments episodic memory as early predictor AD

  • aMCI more likely to convert to AD than naMCI
  • aMCI referred to as “MCI due to AD” (memory impairment + biomarkers)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do memory impairments compare with preclinical biomarkers for AD? (Jedynak et al., 2012)

Hypothetical model of changes in biomarkers for AD (Jack et al., 2010)

A

(Jedynak et al., 2012)

  • Used (Jack et al., 2010) Model but added memory
  • Delayed free recall Rey Auditory Verbal Learning Test (RAVLT30): earliest predictor AD. Preceded hippocampal volume, amyloid beta and tau.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Early cognitive predictors AD

  • Stable memory impairments may worsen shortly before symptoms AD:
  • Lange et al. (2002)
A

Stable memory impairments may worsen shortly before symptoms AD

Lange et al. (2002):

  • participants completed at least two annual evaluations.
  • NC participants classified as nondemented at both evaluations.
  • AD diagnosed with possible or probable AD at both evaluations.
  • Preclinical AD diagnosed with possible/probable AD at last evaluation AND normal/MCI in preceding evaluation

Performance preclinical AD group on CVLT at 2, 1 and 0 years before diagnosis. Little difference APOE 4 positive or negative (Lange et al., 2002).

  • it seems like decline is most steep in those shortly before being diagnosed.
  • Little difference APOE 4 positive or negative (Lange et al., 2002).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Early cognitive predictors AD.

Episodic memory

EF

Semantic Knowledge

(Mickes et al , 2007)

A
  • Converters: older adults who were cognitively normal 1 and 2 years prior to diagnosis probable AD (in year n)
  • Sharp drop memory years before diagnosis.
17
Q

Early cognitive predictors AD

  • Decline in episodic memory related to progress of neuropathology?
A

Rapid decline shortly before clinical stage:

  • point where compensation increasing neuropathology no longer possible
18
Q

Neuropsychological differences in preclinical AD (Han et al., 2017)

  • Meta-analysis, 71 studies
  • Cognitively healthy participants
  • Biomarkers amyloid-positive (Presence of Alzheimer pathology) or amyloid negative
    • PET or CSF
A
  • Amyloid positive groups < amyloid negative groups on cognitive measures (they performed poorer) including:
    • Global cognitive function
    • Memory
    • Language
    • Visuospatial ability
    • Speed of processing
    • Executive functioning
  • Amyloid positive groups > amyloid negative groups on measures premorbid functioning (WTAR: The Wechsler Test of Adult Reading, NART: National Adult Reading Test)
    • so they were better than those without the pathology before the disease emerged
  • Detectable cognitive differences occur early in course AD
    • Not only memory or EF affected
19
Q

Associated clinical features AD.

  • Behavioural disturbances or neuropsychiatric symptoms (NPS).
A
  • Over course of disease, large majority (80%) persons with AD experience behavioural disturbances (Lyketsos et al., 2002)
  • Behavioural disturbances greater burden family and caregivers than cognitive impairments
20
Q

Associated clinical features of AD

  • Prevalence behavioural disturbances (Lyketsos et al., 2002)
    • N = 258 persons diagnosed with AD
    • Neuropsychiatric Inventory (NPI) completed by informant
  • Review and meta-analysis (Zhao et al., 2016)
    • 48 studies
    • > 10.000 persons with AD
    • 12 NPS of NPI
A
  • Most common: apathy, agitation, depression, sleep disturbances and irritability
    • 50% persons with MCI behavioural disturbances over the course of condition
  • Graph: (Zhao et al., 2016)
    • apathy, depression, aggression most common
      • Prevalence apathy – affected by education level and severity cognitive impairments
      • Prevalence depression - affected by age
      • Prevalence aggression - affected by age and duration of disease
    • Least common euphoria
    • Wide variety in prevalence
21
Q

Interventions in AD

  • general
A
  • No existing intervention can cure AD or stop its progression
  • At best interventions can slow down rate of decline
22
Q

Pharmacological interventions in AD

  • For cognitive symptoms (symptomatic)
A
  • For cognitive symptoms (symptomatic)
    • Acetylcholinesterase inhibitors – to increase ACh levels
      • Donepezil, rivastigmine, galantamine
    • Glutamate antagonist – to reduce activity glutamate neurotransmitter
      • Memantine
    • Positive effects on cognition and daily functioning
    • Limited time (months to several years)
    • Reviews effects acetylcholinesterase inhibitors and glutamate antagonist (DiSanto et al., 2013; Tan et al., 2014)
      • Effects ACHEIs not influenced by AD severity
      • Memantime more effective in more severe AD
      • some patients can’t take any of these due to severe side-effects
23
Q

Pharmacological interventions in AD.

  • For behavioural symptoms
A
  • Depression – antidepressives, mood stabilizing medication
  • Anxiety – antidepressives, benzodiazepines (risk adverse effects)
  • Agitated behaviour – antipsychotics (severe side-effects, not recommended for routine use)
24
Q

Interventions

  • Nonpharmacological interventions
A
  • Cognitive training
    • Review Bahar-Fuchs et al. (2013): no benefit over control condition
    • CT stand alone – general cognition, small effect in people with dementia (Hill et al., 2017 review)
      • Effective studies more stimulating variations: Wii, VR
    • often cognitive ability only increases in the task that was trained and not generally
  • Cognitive rehabilitation
    • aim to improve daily functioning via compensation
    • Positive effects on memory, sense of competence, QoL (Clare et al., 2010)
    • Individualized intervention, compensatory aids and strategies.
  • Cognitive stimulation
    • aim is to engage in poritive experience (singing, playing etc.)
    • Positive effect on cognition and wellbeing/QoL
    • No effect daily functioning or behaviour (Woods et al., 2012, review)
  • Computer-based interventions - CT, CR, CS, cognitive recreation (Garcia-Casal et al., 2017, review)
    • Modest effects cognition, depression and anxiety
    • No effect on daily functioning
25
Q

Interventions for AD.

Nonpharmacological interventions:

  • Interventions for caregivers
A
  • Important management behavioural symptoms:
    • improve caregivers’ knowledge of AD
    • identify, modify factors cause/exacerbate behavioural symptoms
  • Improve CG wellbeing
    • PWD can live at home longer
  • CG present intervention
    • Cost-effectiveness
26
Q

Interventions

¨Nonpharmacological interventions

  • effects overall:
A
  • Effects cognition or behaviour usually small
  • Most effective in earlier stages AD
  • Multi-component intervention more effective